Skip to Main Content

Jeffrey Bluestone, the prominent immunologist, has decided to leave his position as president of the Parker Institute for Cancer Immunotherapy, the research effort funded by billionaire Sean Parker, and strike out on his own as CEO of a new company, Sonoma Biotherapeutics.

The departure, which occurred in December, means Bluestone is resigning from an organization that is trying to develop a new model for advancing cancer research and heading to a biotech startup that’s trying to do it in a more familiar way. Sonoma is trying to develop therapies that harness the immune system by treating not cancer but diseases of the immune system like rheumatoid arthritis, multiple sclerosis, and inflammatory bowel disease.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

  • Definitely agree, but in turning off certain T-Cells in the immune system for a changing virus environment…does that mean if that T-Cell is needed again to fight off a disease that the patient can’t become immune. Is more at risk health wise?

  • I have struggled with a number of Autoimmune Diseases since 1986. I have
    been in Clinical Trials at NIH, for Lupus. I do, however have many other related autoimmune diseases. If I can be of any help, in terms of medical history, or personal experiences, I would be more than Happy to help.
    My family has been wiped out by these diseases, including my Mother at age 29, and my sister at age 39. I also have had other family members affected(Familial Lupus). Please keep me informed, and let me know how
    I can be of Help. Thank you……Kind Regards….Ruth

Comments are closed.